

Ordering hydroxychloroquine at KHN

The dose is hydroxychloroquine is 400 mg BID x2 doses, then 400 mg QD x4 days (five days total)

Ordering in Epic will be a modification of current panel with guidance and 2 order questions

- QTc < 500? (most recent QTc will be displayed)
- Meets criteria for administering HCQ (criteria will be displayed, *see next slides*)

The team is aware that most patients that meet admission criteria are candidates for HCQ

This fits with the intention of preventing progression of disease to the critical phase of respiratory failure

Hydroxychloroquine is in very short supply. Clinicians are expected to follow these guidelines.

Indications for hydroxychloroquine When SARS CoV-2 status is pending

Patients with fever (temp > 100.4), cough, SOB and two (2) of:

- Age > 65
- Cardiovascular disease, excluding hypertension as a sole cardiovascular diagnosis
- Diabetes with A1c level >7.5%
- Chronic pulmonary diseases, including asthma
- End-stage renal disease
- Advanced liver disease
- Blood disorders (e.g., sickle cell disease)
- Neurologic or neurodevelopmental disorders
- Post–solid organ transplantation, on immunosuppressive therapy
- Use of biologic agents for immunosuppression
- Undergoing treatment with chemotherapy or immunotherapies for malignancy
- Within 1 year post–marrow transplant
- Undergoing treatment for graft-versus-host disease
- HIV infection, with CD4 cell count <200 copies/mm³

- Critical illness as measured by CURB65 ≥ 2

- O₂ sat < 92% on room air (or their usual home O₂)

Indications for hydroxychloroquine When SARS-CoV-2 is positive

Any one (1) of :

- Age > 65
- Cardiovascular disease, excluding hypertension as a sole cardiovascular diagnosis
- Diabetes with A1c level >7.5%
- Chronic pulmonary diseases, including asthma
- End-stage renal disease
- Advanced liver disease
- Blood disorders (e.g., sickle cell disease)
- Neurologic or neurodevelopmental disorders
- Post–solid organ transplantation, on immunosuppressive therapy
- Use of biologic agents for immunosuppression
- Undergoing treatment with chemotherapy or immunotherapies for malignancy
- Within 1 year post–marrow transplant
- Undergoing treatment for graft-versus-host disease
- HIV infection, with CD4 cell count <200 copies/mm³
- Critical illness as measured by CURB65 ≥ 2
- O₂ sat < 92% on room air (or their usual home O₂)

Exclusions for hydroxychloroquine

- Pregnancy / breastfeeding
 - Evidence of fetal harm with HCQ, consult ID
- Terminal illness
 - Exclusive of COVID-19
- Previous course of HCQ
 - Consult with pharmacy / ID for exception
- Seizure disorder
- Retinopathy
- Weight less than 50 kg
- QTc > 500

Above represents synthesis of

- KHN ID
- KHN cardiology
- Johns Hopkins
- Mass General
- University of Washington
- UpToDate (multiple citations)
- BARDA letter (strategic national stockpile release of HCQ)

For patients with QTc 450-500, then ECG in 3 days.